- United States
- /
- Healthcare Services
- /
- NasdaqGS:NRC
National Research First Quarter 2025 Earnings: EPS: US$0.25 (vs US$0.27 in 1Q 2024)
National Research (NASDAQ:NRC) First Quarter 2025 Results
Key Financial Results
- Revenue: US$33.6m (down 5.0% from 1Q 2024).
- Net income: US$5.79m (down 9.0% from 1Q 2024).
- Profit margin: 17% (in line with 1Q 2024).
- EPS: US$0.25 (down from US$0.27 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
National Research shares are up 1.6% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for National Research (1 is concerning!) that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if National Research might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:NRC
National Research
Provides analytics and insights that facilitate measurement and improvement of the patient and employee experience.
Fair value second-rate dividend payer.
Market Insights
Community Narratives

